Bradrick Named to Spectrum Pharmaceuticals Board of Directors
9 May 2022 - - US-based biopharmaceutical company Spectrum Pharmaceuticals (NASDAQ: SPPI) has appointed Brittany Bradrick to its board of directors, the company said.

Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience.

Bradrick has served as the chief financial officer of Neurelis, Inc. since October 2021. Prior to joining Neurelis, Bradrick was chief operating officer and chief financial officer at ViaCyte.

She previously served in strategy and corporate development positions for 10 years at Insulet Corp. as vice president, Strategy and Corporate Development and at Abbott Diabetes Care as the Head of Global Business Development.

Prior to these positions, Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years.

Bradrick began her career as a Federal Reserve Bank Examiner. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace.

Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future.